CCDM Clinical Trial Design 3

Question 1

What is the role of a Data Safety Monitoring Board (DSMB) in clinical trial design?

Accepted Answer

To independently review accumulating safety and efficacy data and recommend trial continuation, modification, or termination

Answer

A DSMB is an independent committee that periodically reviews unblinded interim data to protect participant safety and ensure ongoing trial integrity.

Question 2

In a stratified randomization scheme, stratification variables are chosen primarily to:

Accepted Answer

Ensure balance of key prognostic factors across treatment groups

Answer

Stratification ensures that important prognostic factors (e.g., disease severity, age group) are balanced between treatment arms, reducing confounding.

Question 3

Which endpoint type is defined as a direct measure of how a patient feels, functions, or survives?

Accepted Answer

Clinical endpoint

Answer

Clinical endpoints directly measure patient outcomes meaningful to patients and clinicians, such as survival, symptom relief, or functional status.

Question 4

In the context of clinical trial design, what is a 'run-in period'?

Accepted Answer

A pre-randomization phase used to assess eligibility, compliance, or baseline response

Answer

A run-in period precedes randomization and is used to evaluate patient suitability, wash out prior medications, or assess baseline compliance.

Question 5

A Bayesian adaptive design differs from a frequentist design primarily in that it:

Accepted Answer

Incorporates prior probabilities and updates them with accumulating trial data

Answer

Bayesian designs update prior probability distributions with incoming trial data to produce posterior probabilities, enabling more flexible interim decision-making.

(CCDM) Certified Clinical Data Manager Practice Test

(CCDM) Certified Clinical Data Manager Practice Test

CCDM Clinical Trial Design 3